Shin Nippon Biomedical Laboratories, Ltd. (JP:2395) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Shin Nippon Biomedical Laboratories (SNBL) has announced a collaboration with Astellas Pharma to enhance the drug discovery ecosystem in Tsukuba City by providing non-clinical study support at the SakuLab™-Tsukuba innovation center. SNBL, Japan’s largest nonclinical CRO, will offer its expertise in drug discovery to support startups, academia, and pharmaceutical companies at Tsukuba, one of Japan’s leading life science centers. This partnership aims to accelerate the development of new drugs and advanced technologies within the Tsukuba ecosystem.
For further insights into JP:2395 stock, check out TipRanks’ Stock Analysis page.